Indivior Pharmaceuticals, Inc. — Form 8-K
Filed September 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Indivior's Board declared a special cash dividend of $8.13 per share payable to shareholders of record on October 30, 2026, contingent upon closing of the previously announced merger with Supernus Pharmaceuticals (expected ~November 2, 2026). Payment is anticipated November 6, 2026 if merger closes. Supernus shareholders will not receive the special dividend on Indivior stock obtained as merger consideration.
Why this rating
Special dividend materially returns capital (~$8.13/share on ~$1.8B market cap = ~13-15% of equity value) to current shareholders, conditional on merger completion. Significant shareholder-friendly action but contingent execution risk limits certainty.
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.